Mergers & Acquisitions ·
CASI Pharmaceuticals sold its equity interests in Alesta Therapeutics B.V. to BioMarin Pharmaceutical Inc., which…
CASICASI Pharmaceuticals, Inc.
CASI Pharmaceuticals sold its equity interests in Alesta Therapeutics B.V. to BioMarin Pharmaceutical Inc., which acquired Alesta. The transaction closed on August 31, 2026, with CASI receiving approximately US$5.9 million in net cash proceeds and retaining potential rights to contingent milestone payments. Alesta retained its ALE1 asset while spinning out non-ALE1 assets prior to closing, and CASI's licensed rights to CID-103 remain unchanged. CASI Pharmaceuticals is a clinical-stage biopharmaceutical company developing CID-103 for organ transplant rejection and autoimmune diseases.